HomeCompareMNMD vs EPRT

MNMD vs EPRT: Dividend Comparison 2026

MNMD yields 10.58% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $23.1K in total portfolio value· pulled ahead in Year 7
10 years
MNMD
MNMD
● Live price
10.58%
Share price
$18.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$2,053.05
Full MNMD calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — MNMD vs EPRT

📍 EPRT pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNMDEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNMD + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNMD pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNMD
Annual income on $10K today (after 15% tax)
$899.00/yr
After 10yr DRIP, annual income (after tax)
$1,745.09/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,169.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNMD + EPRT for your $10,000?

MNMD: 50%EPRT: 50%
100% EPRT50/50100% MNMD
Portfolio after 10yr
$51.8K
Annual income
$7,446.88/yr
Blended yield
14.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

MNMD
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$28.00
+48.1% upside vs current
Range: $28.00 — $28.00
Altman Z
5.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNMD buys
0
EPRT buys
0
No recent congressional trades found for MNMD or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNMDEPRT
Forward yield10.58%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$40.2K$63.4K
Annual income after 10y$2,053.05$12,840.73
Total dividends collected$15.5K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$28.00$35.50

Year-by-year: MNMD vs EPRT ($10,000, DRIP)

YearMNMD PortfolioMNMD Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,758$1,057.64$11,205$505.18+$553.00MNMD
2$13,743$1,162.18$12,672$682.46+$1.1KMNMD
3$15,974$1,269.54$14,490$930.48+$1.5KMNMD
4$18,472$1,379.15$16,786$1,282.69+$1.7KMNMD
5$21,255$1,490.43$19,753$1,791.56+$1.5KMNMD
6$24,346$1,602.82$23,677$2,541.64+$669.00MNMD
7← crossover$27,766$1,715.78$29,008$3,672.99$1.2KEPRT
8$31,538$1,828.79$36,463$5,425.08$4.9KEPRT
9$35,687$1,941.36$47,238$8,221.57$11.6KEPRT
10$40,239$2,053.05$63,385$12,840.73$23.1KEPRT

MNMD vs EPRT: Complete Analysis 2026

MNMDStock

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Full MNMD Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this MNMD vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNMD vs SCHDMNMD vs JEPIMNMD vs OMNMD vs KOMNMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.